FGF21 and metabolic dysfunction-associated steatotic liver disease: In particular, recent studies have focused on fibroblast growth factor 21 (FGF-21), a hepatoprotective protein with modulatory effects on glucose and insulin sensitivity, that shows a condition of resistance in subjects with NAFLD, with further worsening in the case of Non-Alcoholic Steatohepatitis (NASH) [11].